


Certificate of Mailing

"Certificate of Express Mail" mailing label number EV 332 010 784 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Mail Stop: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 15, 2003.

By: Printed: Olga Bandman

07/15/03
U.S. PTO
17611

21909 U.S. PTO
10/621263

07/15/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)

Mail Stop: Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is a request for filing a DIVISIONAL application under 37 CFR 1.53(b) of pending prior application Serial No. 09/802,633, filed on March 8, 2001, which is a DIVISIONAL of prior U.S. patent application no. 09/032,523, filed on February 27, 1998, now issued patent number 6,232,454, both entitled HUMAN PROTEINASE MOLECULES, all of which are incorporated herein by reference.

<input checked="" type="checkbox"/>	Enclosed is a specification corresponding to the prior application, U. S. Application Serial No. 09/802,633, filed on March 8, 2001, including the oath or declaration as originally signed. The specification does not contain any subject matter that would have been new matter in the prior application.
<input checked="" type="checkbox"/>	Cancel in this application original claims 3-10, 12-29 and 46-61 before calculating the filing fee, without prejudice or disclaimer. Applicants submit that these claims were included in the application as filed in the interest of providing notice to the public of certain specific subject matter intended to be claimed, and are being canceled at this time in the interest of reducing filing costs. Applicants expressly state that these claims are not being canceled for reasons related to patentability, and are in fact fully supported by the specification as filed. Applicants expressly reserve the right to reinstate these claims or to add other claims during prosecution of this application or a continuation or divisional application. Applicants expressly do not disclaim the subject matter of any invention disclosed herein which is not set forth in the instantly filed claims.
<input checked="" type="checkbox"/>	The inventors of the invention being claimed in this application are: Olga Bandman, Neil C. Corley, Karl J. Guegler and Mariah R. Baughn.
<input checked="" type="checkbox"/>	The prior application is assigned of record to <u>Incyte Corporation, formerly known as Incyte Genomics, Inc., also formerly known as Incyte Pharmaceuticals, Inc.</u> , recorded on May 22, 1998, at reel 9335/frame 0085.

The power of attorney of the prior application is to:

The associate power of attorney in the prior application is to:

<input checked="" type="checkbox"/>	The invention was not made by an agency of the United States Government or under a contract with an agency of the United States Government.
-------------------------------------	---

ENCLOSURES

<input checked="" type="checkbox"/>	Application Data Sheet (ADS) (4 pp.).
<input checked="" type="checkbox"/>	Blanket Exemption from Requirements Under § 42 U.S.C. 2182 Letter (1 pg.).
<input checked="" type="checkbox"/>	In accordance with 37 CFR 1.63(d), a copy of the originally signed declaration showing applicants' signatures as filed on May 22, 1998 (5 pp.).

Submission of Formal Drawings (1 pg.); and Seventeen (17) Sheets of Formal Drawings, including Figures 1A, 1B, 1C, 2A, 2B, 2C, 2D, 2E, 3A 3B, 3C, 3D, 3E, 4A, 4B, 5A and 5B.

Information Disclosure Statement (2 pp.); and List of References Cited PTO-1449 (2 pp.).

Copy of previously submitted Certification under 37 C.F.R. §3.73(b), Revocation of Power of Attorney and Appointment of New Attorneys (2 pp.).

Submission under 37 CFR § 1.821-1.825 Sequence Listing (1 pg.).

One (1) Substitute CRF diskette containing the sequence listing.

Other: Copy of Documents Filed in Parent Case on April 7, 2003 to Amend Inventorship and USPTO Communication (6 pp.).

CLAIMS AS FILED

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity		Basic Fee	
				Rate	Fee	\$	750.00
Total Claims	19	-20	0	x \$18	0	\$	0
Indep. Claims	1	-3	0	x \$84	0	\$	0
Multiple Dependent Claim(s), if any				+ \$280	0	\$	0
					Filing Fee:	\$	0

FEE CALCULATION AND METHOD OF PAYMENT

The Fee has been calculated as follows:

Fee for filing a [Divisional/Continuation] Application Under 37 CFR 1.16 (a): \$ _____

Please charge Deposit Account No. **09-0108** in the amount of: \$ _____

Applicants hereby authorize the Commissioner to treat any concurrent or future reply in this application that requires a petition for an extension of time under 37 CFR 1.136(a) to be timely, as incorporating a petition for extension of time for the appropriate length of time; and to charge all required fees, including fees under 37 CFR 1.16, 1.17, and all required extension of time fees, or to credit any overpayment, to Deposit Account 09-0108. This sheet is enclosed in duplicate.

CORRESPONDENCE ADDRESS

(Customer No. 27904)

INCYTE CORPORATION
LEGAL DEPARTMENT
3160 Porter Drive
Palo Alto, California 94304

Phone: (650) 855-0555
Fax: (650) 845-4166 or
(650) 849-8886

Date: 15 July 2003

By: Cathleen M. Rocco Reg# 46,172
for Yu-Mei Eureka Wang
 Reg. No. 50,510
 Direct Dial Telephone: (650) 621-8740

Attorney or Agent of record.

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Issue Fee, Commissioner for Patents, Washington, D.C. 20231 on April 7, 2003.

By: Lyza Familiar Printed: Lyza Familiar

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bandman et al.

Title: HUMAN PROTEINASE MOLECULES

Serial No.: 09/802,633 Filing Date: March 08, 2001

Examiner: Huff, S. Group Art Unit: 1642

Box Issue Fee

Commissioner for Patents
Washington, D.C. 20231

FEE TRANSMITTAL SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard; and
2. Request to Amend Inventorship Under 37 C.F.R. § 1.48(b) (2 pp.).

The fee has been calculated as shown below.

X Fee for Request to Amend Inventorship Under 37 CFR § 1.48(b) and \$130.00
X Please charge Deposit Account No. 09-0108 in the amount of : \$130.00

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE CORPORATION

Date: 7 April 2003

Yu-Mei Eureka Wang
 Yu-Mei Eureka Wang
 Reg. No. 50,510
 Direct Dial Telephone: (650) 621-8740

Customer No.: 27904
 3160 Porter Drive
 Palo Alto, California 94304
 Phone: (650) 855-0555
 Fax: (650) 845-4166